Pressure BioSciences New Eco-Friendly Agrochem Subsidiary Receives Over $1,000,000 in Orders in First Month of Operations

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

PBI Agrochem Integration into the Sales Channels of Its Planned Asset Acquisition of a Global,

 Environmentally Responsible Agrochem Company is Expected to Result in a Significant Q3 2021 Impact

South Easton, MA, August 12, 2021 – Pressure BioSciences, Inc. PBIO (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced that its newly-formed agrochemicals subsidiary - PBI Agrochem, Inc. - has received initial purchase orders for over $1M of eco-friendly agrochemical products for delivery in 2021.  Just three weeks ago, the Company announced the formation of its new agrochemicals division in anticipation of the planned asset acquisition of a global agrochemicals products business focused on organically natural and environmentally responsible products. 

PBI’s President and CEO Richard T. Schumacher explained the fast development of early sales: “With integration planning for this acquisition well underway, PBI Agrochem placed an initial order for specialized, proprietary bulk material in July and began establishing U.S. warehousing, processing, and final product packaging facilities. Our objective was to insert PBI Agrochem into the supply chain and sales channels of our acquisition target, in order to capture early sales revenues that we believe could have an immediate, accretive impact upon PBI’s overall operating results.  These efforts have resulted in over $1M in 2021 customer orders for eco-friendly and effective agrochemical pest control and growth stimulant products.” 

Mr. Schumacher continued: “We anticipate that the delivery and booking for most of these orders will occur during the third quarter 2021. PBI investors who have followed and supported the Company through recent years understand that this new incremental revenue from PBI Agrochem represents a potential doubling (or more) of quarterly revenues, when added to sales of PBI’s existing core products and services. With additional orders expected to arrive over the coming weeks and months, we believe Q4 2021 could substantially exceed the results of Q3 2021. Our new agrochem sales are expected to accelerate PBI’s rapidly improving growth trajectory and should contribute substantially towards our planned transition to profitability by the end of 2022.”

Mr. John B. Hollister, Director of Sales and Marketing at PBI, said: “The market potential in agrochemicals is enormous, driven by the intersection of burgeoning global population growth and accelerating environmental consciousness and priorities. Our positioning in organically natural and ecofriendly product solutions places PBI squarely within the hottest growth generation in this sector.  Closing on over $1M of orders in the first month of PBI Agrochem operations is a welcome signpost on the road to major growth and profitability for our agrochem operations.  The broad array of eco-friendly products being integrated into PBI will address a diversity of agrochem client needs throughout the year, from fertilizing young plants, to mitigating microbial and larger animal threats, to enhancing the appearance and appeal of finished produce.”

PBI’s Board Chairman Jeffrey N. Peterson commented on the synergies achieved in PBI’s move into agrochemicals: “The creation of many organically natural and effective, environmentally-friendly agrochemical products is typically achieved through utilization of essential oil active ingredients extracted from plants, such as the already popular use of orange peel essential oil in ant sprays. PBI’s breakthrough Ultra Shear Technology™ (UST™) platform, for creation of extremely low-droplet size nanoemulsions of oils in water, offers added value for a new generation of products with improved effectiveness and economics, allowing less active material to deliver higher effectiveness when applied or consumed.  We are aggressively driving the creation of pioneering partnerships around UST in application sectors from pharmaceuticals to nutraceuticals to food/beverage and many more areas, as PBI’s core strategy for growth and profitability. We have singled out agrochemicals for a more aggressive forward integration into an applications sector for UST, in a bid to accelerate the cycle of education, trial, market demonstration, product differentiation, and uniquely advantaged growth.  We are delighted to be sharing these insights into PBI’s expected accelerating growth trajectory and path to profitability with our loyal investor base.”

The asset acquisition is subject to certain conditions, including the completion of all due diligence and acquisition financing.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. PBIO is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com 

Please visit us on Facebook, LinkedIn, and Twitter.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.